David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

A 19-year-old is celebrating being cancer-free – a year after he was told that there was no hope and to “go home and make ...

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

FORCIT is planning to invest more than EUR 200 million in the construction of a new TNT production facility in Pori, Finland. TNT is a widely used explosive that has been used in military applications ...

Blue Faery is proud to announce the continuation of its annual Love Your Liver campaign during Black History Month, marking the fourth consecutive year of this impactful and award-winning initiative.

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...